Medical Developments International Limited · ASX:MVP
Medical Developments International — Shareholder Meeting (October 2014)
10 slides from Medical Developments International's shareholder meeting presentation, Oct 28, 2014
Slide 1: Medical Developments International Annual General Meeting
For personal use only Medical Developments International Annual General Meeting 28 October 2014 0 0
Slide 2: Exciting future
Exciting future For personal use only Penthrox has global application and the capacity to dominate specific analgesic markets around the world. Our respiratory and medical devices are leaders in many of the markets we operate in. We have achieved a number of key strategic milestones this year, movin
Slide 3: Penthrox future
Penthrox future For personal use only We are looking forward to receiving positive feedback from the European regulatory authorities regarding the approval of Penthrox for sale in the United Kingdom, France, Ireland and Belgium before the end of this calendar year. If successful, we will be in a pos
Slide 4: Penthrox regulatory submissions
Penthrox future For personal use only During FY14 we used our Regulatory Dossier to make submissions to: United Kingdom; Saudi Arabia; France; Belgium; Ireland; Russia; Israel; Singapore. We are preparing applications in Hungary, Mexico, Malaysia and Hong Kong which we hope will be lodged in the nex
Slide 5: Penthrox CSIRO project
Penthrox future For personal use only We expect to have our CSIRO project completed during FY15. If successful it will provide valuable intellectual property for MDI. 4
Slide 6: Respiratory distribution deals
Respiratory future For personal use only We have completed deals to distribute our range of respiratory devices in the: United Kingdom; Italy; Luxemburg; Netherlands; Belgium; Greece; Singapore; Hong Kong. This adds to our established networks in: Australia, Germany, Switzerland, Austria, Canada, UA
Slide 7: Respiratory international sales
Respiratory future For personal use only International sales are almost four times (4x) higher than for the same period last year. We are looking to sign additional distribution deals in the coming months, including in the USA. We expect sales to grow for the rest of FY15 and beyond. 6
Slide 8: Innovation, Research and Product Development
Innovation, Research and Product Development For personal use only MVP increased its investment, energy and focus in its internal capacity for product innovation, development and research. Our new range of anti-static respiratory devices will be available for sale during FY15 and will be leaders in
Slide 9: Trading update
Trading update For personal use only Our business has recovered strongly in the first quarter FY15. • Sales are up 22% (year on year) • Gross Margin has improved • Penthrox sales are up 36% (year on year) • Respiratory Device sales are up 88% (year on year) • EBIT is four times higher compared to Q1
Slide 10: Conclusion
Conclusion For personal use only Our Respiratory Device business is recovering and will provide long term sustainable sales growth for our company. Penthrox is a category leading drug in Australia and we expect it can dominate many of the trauma and minor surgical procedure markets around the world.
Medical Developments International — Shareholder Meeting (October 2014) on 6ix